肝脏 ›› 2020, Vol. 25 ›› Issue (10): 1058-1061.

• 肝癌 • 上一篇    下一篇

冷循环微波消融联合TACE术治疗原发性肝癌的临床研究

吴洁, 董刚, 刘婷婷, 孙璐璐   

  1. 451299 河南 郑州大学第一附属医院超声介入科
  • 收稿日期:2020-02-22 出版日期:2020-10-31 发布日期:2020-12-18
  • 通讯作者: 董刚
  • 基金资助:
    河南省高等学校重点科研项目计划(No:18A320041)

Clinical study of cold cycle microwave ablation combined with TACE in the treatment of primary liver cancer

WU Jie, DONG Gang, LIU Ting-ting, SUN Lu-lu   

  1. Department of Ultrasound Intervention, the First Affiliated Hospital of Zhengzhou University, Henan 451299, China
  • Received:2020-02-22 Online:2020-10-31 Published:2020-12-18
  • Contact: DONG Gang

摘要: 目的 研究冷循环微波消融联合肝动脉化疗栓塞(TACE)术治疗原发性肝癌(HCC)的临床疗效。方法 将90例HCC患者纳入研究对象,以随机数表法分为观察组(n=45)与对照组(n=45),对照组接受TACE手术治疗,观察组在对照组基础上接受冷循环微波消融治疗。对比两组临床疗效、住院时间、住院费用及治疗前后简明健康状况调查问卷量表(SF-36)评分,最后对比两组治疗后不良反应发生情况。结果 观察组治疗后有效率及疾病控制率分别为77.78%、86.67%,显著高于对照组的62.50%、68.89%,P<0.05。观察组住院时间、住院费用显著多于对照组,P<0.05;观察组治疗后SF-36评分显著高于治疗前及对照组治疗后,P<0.05。两组不良反应总发生率对比无显著差异,P>0.05。结论 冷循环微波消融联合TACE术治疗HCC临床疗效显著,可有效改善患者生活质量。

关键词: 原发性肝癌, 冷循环微波消融, 肝动脉化疗栓塞, 生活质量

Abstract: Objective To study the clinical effect of cold cycle microwave ablation combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary hepatocellular carcinoma (HCC). Methods There were 90 HCC patients included in the study, divided into the observation group (n = 45) and the control group (n = 45) by the random number table. The control group received TACE, and the observation group received TACE and cold cycle microwave ablation. Clinical efficacy, time of hospitalization, cost of hospitalization, pretreatment and posttreatment Short Form-36 (SF-36) score, and the occurrence of adverse reactions after treatment was compared between the 2 groups. Results The response rate and disease control rate of the observation group were 77.78% and 86.67, respectively, which were significantly higher than those of the control group (62.50% and 68.89%, P<0.05). The time and cost of hospitalization in the observation group were significantly more than those in the control group (P<0.05). The posttreatment SF-36 score in the observation group was significantly higher than pretreatment score and posttreatment score in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the 2 groups (P>0.05). Conclusion The cold cycle microwave ablation combined with TACE has significant efficacy in the treatment of HCC, which can effectively improve patients’ quality of life.

Key words: Primary liver cancer, Cold cycle microwave ablation, Transcatheter arterial chemoembolization, Quality of life